What the trial was testing
The trial enrolled 201 patients with multiple myeloma. The study was sponsored by M.D. Anderson Cancer Center and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
The lower dose caused half as many cases of pneumonia and mouth sores compared to the higher dose.
The Lancet. Haematology · 2018 · NCT01572662
These findings — that very low death rate in first 100 days after transplant in both dose groups — were published in the The Lancet. Haematology and represent the headline result of the study.
Researchers tracked outcomes across 201 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with multiple myeloma, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
If you're older or have other health conditions and need a stem cell transplant for blood cancer, this study suggests a lower dose of the prep drug busulfan might be gentler on your body without being less safe. This was an early-stage study testing the best dose. Talk to your transplant team about which conditioning approach is right for you.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open multiple myeloma trials
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).
Institut Paoli Calmettes Multiple Myeloma Database
Database of Institut Paoli-Calmettes patients diagnosed with multiple myeloma